You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥-B(06855.HK)公佈APG-2575最新臨牀進展 復發╱難治慢性淋巴細胞白血病患者客觀緩解率達到70%
格隆匯 12-10 08:12

格隆匯 12 月 10日丨亞盛醫藥-B(06855.HK)發佈公告,亞盛醫藥宣佈該公司在研1類新藥Bcl-2抑制劑APG-2575的最新臨牀進展,展示了其具有較大的治療潛力。

根據披露,APG-2575是亞盛醫藥自主研發的新型口服Bcl-2選擇性小分子抑制劑,通過選擇性抑制Bcl-2蛋白來恢復腫瘤細胞程序性死亡機制(細胞凋亡),從而達到治療血液及實體腫瘤的目的。APG-2575對Bcl-2具有高度的選擇性。APG-2575穿過細胞膜進入細胞後選擇性與綫粒體膜上的抗凋亡蛋白Bcl-2結合,阻斷Bcl-2與促凋亡蛋白BIM形成蛋白—蛋白複合物,釋放出促凋亡蛋白BIM,後者進一步激活細胞凋亡的一系列程序,最終導致腫瘤細胞凋亡。

APG-2575是首個在中國進入臨牀階段的、本土研發的Bcl-2選擇性抑制劑。作為單藥,APG-2575對於Bcl-2依賴的腫瘤細胞具有強的抗腫瘤活性,並且與其他抗癌藥物組合表現出更廣泛的抗腫瘤活性。APG-2575現已獲得中國、澳大利亞、美國、歐洲多項Ib及II期臨牀試驗許可,並正在全球同步推進包括多個血液腫瘤適應症的臨牀開發。

在全球範圍內,共有9項臨牀研究正在進行中,合計100多例患者接受APG2575給藥,劑量從20mg至1200mg不等,涉及的疾病包括慢性淋巴細胞白血病(CLL)、濾泡性淋巴瘤(FL)、套細胞淋巴瘤(MCL)、瀰漫大B細胞淋巴瘤(DLBCL)、多發性骨髓瘤(MM)、急性髓系白血病(AML)、高白細胞急性白血病(HCL)等。此外,APG-2575針對復發╱難治CLL(r/rCLL)的臨牀研究已入組30多位患者,初步臨牀研究結果顯示,在可評估患者中的客觀緩解率(ORR)達到70%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account